



Long-term Follow-up of Patients receiving Intraocular Pressure-lowering Medications as Cataract Surgery Candidates: A Case–control Study

¹Georgios Bontzos, ²Michail Agiorgiotakis, ³Efstathios T Detorakis

ABSTRACT

Aim: In this study, we reviewed demographics and biometric characteristics among patients receiving chronic β -blockers and prostaglandins (PGs) for primary open-angle glaucoma. We compared the age at the time of cataract surgery in different patient groups and in a control group which was not under any medication.

Materials and methods: Retrospective chart review of glaucomatous patients who underwent cataract extraction at the Department of Ophthalmology of the University Hospital of Heraklion, Crete, Greece, between January 1998 and December 2016 was done. Age at cataract surgery, axial length (AL), and preoperative and postoperative best-corrected visual acuities (BCVAs) were recorded. A cohort of patients without glaucoma who were operated for cataract extraction was also evaluated.

Results: In all, 320 patients were reviewed. There were significant results in mean age difference between the beta-antagonist and the PG group [3.05 years, 95% confidence interval (CI) 1.54–4.57] and between the beta-antagonist group with the patients receiving a combined therapy (3.02 years, 95% CI 1.14–4.91). No significant difference was found between the PG and the combination group. All the three treated groups had a significant lower mean age than the control group at the time of cataract surgery.

Conclusion: Based on our study, we concluded that there might be a possible association between chronic treatment with beta-antagonist agents and earlier cataract surgical time in the treated eye.

Clinical significance: Intraocular pressure control is often usually achieved using ophthalmic agents. Their topical and systemic effects should be monitored precisely. Earlier cataract formation might be an important side effect which the physician has to keep in mind before choosing the suitable medication.

Keywords: Aqueous humor, Beta-antagonists, Cataract, Glaucoma, Prostaglandins.

How to cite this article: Bontzos G, Agiorgiotakis M, Detorakis ET. Long-term Follow-up of Patients receiving Intraocular Pressure-lowering Medications as Cataract Surgery

Candidates: A Case–control Study. *J Curr Glaucoma Pract* 2017;11(3):107-112.

Source of support: Nil

Conflict of interest: None

INTRODUCTION

Cataract is the opacification of the natural crystalline lens and breakdown of the lens protein microarchitecture, which adversely affects the transmission of light onto the retina and degrades optical quality.^{1,2} Cataract still remains a leading cause of visual impairment and blindness worldwide.^{3–7} The importance of risk factor identification for cataract development is evident and identifying strategies to prevent or delay cataractogenesis will be an essential part of clinical ophthalmic practice in the near future. Moreover, cataract may be concomitant with other ophthalmic morbidities, also affecting the aging human population, such as glaucoma.

Currently, intraocular pressure (IOP) reduction is the main goal of glaucoma treatment. Initial therapy is typically pharmaceutical, with topical ophthalmic agents^{8–10} such as PG analogues (e.g., tafluprost), β -adrenergic receptor antagonists (β -blockers e.g., timolol), α -adrenergic receptor agonists (α -agonists; e.g., brimonidine), carbonic anhydrase inhibitors (e.g., brinzolamide), and cholinergic receptor agonists (e.g., pilocarpine).¹¹

The pharmacological mechanism of action of these agents varies. Beta-receptors are expressed throughout the eye, and their antagonists reduce aqueous humor production in the ciliary body by inhibiting synthesis of intracellular cyclic adenosine monophosphate.¹¹ Topical carbonic anhydrase inhibitors reduce aqueous humor production by intervening in the carbonic anhydrase-dependent aqueous formation process.¹¹ Prostaglandins accomplish ocular hypotensive effect by enhancing the uveoscleral outflow when binding to prostaglandin F (FP) receptors. The PGs have a minimal effect on aqueous humor production and episcleral venous pressure. They also modulate outflow facility through the trabecular outflow pathway. There are many supporting studies investigating PG mechanisms in the eye.^{12–15} Finally, α -agonists have a complex action in the aqueous turnover by intervening in both production and outflow mechanisms.^{16,17}

^{1,2}PhD Student, ³Associate Professor

^{1,3}Department of Ophthalmology, University Hospital of Heraklion, Crete, Greece

²Institute of Vision and Optics, University of Crete, Crete, Greece

Corresponding Author: Georgios Bontzos, PhD Student Department of Ophthalmology, University Hospital of Heraklion Crete, Greece, Phone:+302810392730, e-mail: gbontzos@hotmail.gr

Therefore, IOP-lowering medications alter the physiological aqueous humor secretion and outflow. Since the lens lacks blood vasculature, it receives all its nourishment from the aqueous humor. Nutrients diffuse in and out through the constant aqueous humor flow. Therefore, it should be reasonable to hypothesize that a disruption in lens homeostasis can eventually lead to cataract development. This study examines the potential association between long term antiglaucomatous drug therapy and cataract formation, with a view to estimate the added risk for cataract development in topical glaucoma medication users.

MATERIALS AND METHODS

Design

This study was designed as a retrospective assessment of patient data from hospital archives. All charts of patients who underwent first cataract surgery between January 1998 and December 2016 at the Department of Ophthalmology of the University Hospital of Heraklion, Crete, Greece, were reviewed and data from the first operated eye for cataract were obtained. Patients gave informed written consent for cataract surgery. All investigations analyzed in this study have been carried out in compliance with the Helsinki Declaration and were approved by our local ethics committee.

Subjects

Patients who had been receiving topical IOP-lowering medication in the operated eye at the time of surgery were included for analysis. Patients were separated into three subgroups according to their medication treatment mechanism:

Group I: Under monotherapy with a β -blocker (timolol 0.5%),

Group II: Under monotherapy with a PG (latanoprost 0.005% or bimatoprost 0.03%)

Group III: Patients receiving combination of these medications (β -blocker + PG).

Inclusion criteria also were as follows: Patient age ≥ 60 years, primary open-angle glaucoma, and receiving the same medication (β -blocker, PG, or a combination treatment of these two) for at least 5 years before surgery. They were eligible for analysis if they presented with IOP values of < 20 mm Hg in all their monitoring examinations before cataract extraction. Patients' data were excluded from analysis if they had received other IOP-lowering medications like α -agonists or cholinergic receptor agonists at any time, reported with angle-closure glaucoma, congenital and traumatic cataracts, prior history of intraocular surgery,¹⁸ any history of inflammatory

ocular disease,¹⁹ ocular infection or severe dry eye, and diabetes mellitus diagnosed for over a year before cataract surgery. These conditions can hasten the development of cataract as reported in multiple studies.²⁰⁻²⁵ Also, patients receiving topical or systemic corticosteroids for more than 30 days for any medical condition were also excluded.²⁶⁻²⁸ Finally, eyes with AL more than 28 mm were not included since AL greater than 30.0 mm has been associated with reduction in cataract age at surgery.²⁹ Data from all nonglaucomatous patients who had cataract surgery and were age 60+ years at the time of their earliest cataract surgical procedure at the same department and during the same time interval were collected. The same exclusion criteria were followed for that control group.

The age at surgery, AL, as well as preoperative and postoperative (at the 6-month interval) BCVAs were recorded. Morphological information of the type and density of cataract (i.e., nuclear, cortical, subcapsular) was also included. In all, 320 patients were included providing a high observed statistical power throughout analysis; observed *post hoc* power was calculated by using Statistical Package for the Social Sciences (SPSS) version 22 and it was equal to 1.


Statistical Analysis

The SPSS version 22.0 statistical package was used to generate graphs and to perform comparison tests between groups. All tests were two-tailed, and a p-value of 0.05 was determined to represent statistical significance. Normality for each of the four groups was verified by using Shapiro–Wilk test (group I: $p = 0.53$, group II: $p = 0.183$, and group III: $p = 0.155$, and general population group IV: $p = 0.749$, each one greater than $\alpha = 0.05$). Applying Levene's test for homogeneity of variances between groups showed that the variances are unequal ($p = 0.0001$). As the variances and the sample sizes differ, comparisons among the four groups were done using Welch's robust test and Games–Howell *post hoc* test.

RESULTS

The profile of this study is presented in Graph 1 and Table 1. In total, 320 patients were enrolled; 66 were receiving β -blocker topical medication, 98 were receiving PGs, and 78 were receiving a combined treatment of a β -blocker and a PG, either as two different drugs or as a fixed combination. Furthermore, 78 were nonglaucomatous patients who underwent cataract surgery and were assessed as a control group. Comparisons between different groups, standard deviations, and p-values are mentioned in Table 1.

The mean age when patients underwent first cataract surgery was 74.42 (SD = 5.055), and for each subgroup, the mean age is shown in Table 1.



Graph 1: Box plots of age of cataract surgery for different subgroups which are separated based on different medications. Middle line in box represents the median age, lower box bound the first quartile, upper box bound the third quartile, whiskers the 95% confidence interval of the mean

There were statistical significant differences, concerning the age of cataract surgery between groups (β -blockers, PGs, combination, and nonglaucomatus groups; Welch’s robust test, $p \approx 0$). For additional analysis between groups, Games–Howell *post hoc* test was applied. As seen in Table 2, there are significant differences for several comparisons and the p-value for each comparison is reported in Table 2. Comparing the three groups treated for glaucoma with the control group IV shows that mean differences are statistically significant with a younger

mean age in the glaucomatous groups. The mean difference between the control and the β -blocker group is 5.88 (95% CI 3.90-7.86), while the control group and the PG group had a mean difference of 2.82 (95% CI 0.85-4.80). Mean difference between control group and combination group was 2.85 (95% CI 0.59-5.12). Moreover, the mean age difference between β -blockers and PG groups was 3.05 (95% CI 1.54-4.57), and between β -blocker and combination group was 3.02 (95% CI 1.14-4.91), which implies that cataract progression is more rapid in patients treated with β -blockers.

Comparing the mean age of groups treated with PGs and combination treatment revealed no significant difference between the two group means (mean difference 0.03 with 95% CI -1.91-1.84).

DISCUSSION

To the best of our knowledge, the association between treatment with antiglaucomatous β -blockers or PGs and the timing of cataract surgery has not been previously examined. Findings from this study imply that long-term antiglaucomatous treatment with specific β -blockers (timolol 0.5%) and PGs (latanoprost 0.005% or bimatoprost 0.03%) may lead to earlier cataract formation, compared with controls. A point of interest is that patients with glaucoma are in constant follow-up examinations. Cataract progression is monitored as a part of their ophthalmic examination allowing earlier

Table 1: Age variation of cataract surgery for subgroups, based on treatment medication

Variable	n	Mean age	Standard Deviation	95% CI for mean			
				Lower bound	Upper bound	Minimum	Maximum
Beta-blocker	66	71.3182	3.35655	70.4930	72.1433	63	79
PG	98	74.3776	4.08799	73.5580	75.1971	66	84
Combination	78	74.3462	5.24423	73.1638	75.5285	63	85
Nonglaucomatus	78	77.2051	5.63007	75.9357	78.4745	63	90
Total	320	74.4281	5.05529	73.8721	74.9841	63	90

Table 2: Comparison between mean age of each subgroup using Games–Howell *post hoc* test

(I) Medication	(J) Medication	Mean diff. (I-J)	p-value	95% CI	
				Lower bound	Upper bound
Beta-blocker	PG	-3.05937*	0.000003	-4.5764	-1.5423
	Combination	-3.02797*	0.000297	-4.9101	-1.1458
	Nonglaucomatus	-5.88695*	0.000001	-7.8643	-3.9096
PG	Beta-blocker	3.05937*	0.000003	1.5423	4.5764
	Combination	0.03140	0.999970	-1.8487	1.9115
	Nonglaucomatus	-2.82758*	0.001621	-4.8032	-0.8520
Combination	Beta-blocker	3.02797*	0.000297	1.1458	4.9101
	PG	-0.03140	0.999970	-1.9115	1.8487
	Nonglaucomatus	-2.85897*	0.006933	-5.1218	-0.5961
Nonglaucomatus	Beta-blocker	5.88695*	0.000001	3.9096	7.8643
	PG	2.82758	0.001621	0.8520	4.8032
	Combination	2.85897*	0.006933	0.5961	5.1218

*The mean difference is significant at the 0.05 level

detection and probably decision for extraction of a vision impairing cataract.

Glaucoma eye drop therapy would ideally maximize IOP-lowering efficacy and minimize adverse reactions. Several long-term topical and systemic side effects have been reported associated with IOP-lowering topical medications. For example, there are concerns regarding systemic side effects after beta-adrenoreceptor blocking activity in the pulmonary and circulatory system. Topical β -blocker may lower heart rate and blood pressure and may induce asthma and worsen chronic obstructive pulmonary diseases.³⁰⁻³² Timolol drops have also been shown to decrease high-density lipoprotein and increase cholesterol. Diabetics may experience reduced glucose tolerance and hypoglycemic signs and symptoms can be masked.³³ In addition, timolol induces a local anesthetic effect on the ocular surface, leading to poor tear secretion.³⁴ Over time, chronic corneal toxicity from topical ocular medications may cause nerve damage, potentially resulting in neurotrophic keratopathy.

On the contrary, patients treated with topical PG analogues have a higher incidence of dry eye syndrome and Meibomian gland dysfunction.^{35,36} The PGs, and mostly latanoprost, have been associated with developing cystoid macular edema after been administered for ocular hypertension.³⁷ Other benign side effects associated with PGs include eye pruritus, conjunctival hyperemia, periorbital lipodystrophy, and darkening of the iris, eyelashes, and periocular skin.³⁸ In previous studies, PGs used as topical IOP-lowering agents have been questioned for their possible effects in crystalline lens homeostasis.³⁹ Because lens epithelial cells express a high density of FP receptors, the mitogenic activities of PGs may alter lens physiology in long-term treatment.³⁹ In short-term clinical use, the precise role of these PG receptors in lens epithelial cell pathophysiology has not been determined.

Strengths of our study include its long-term follow-up of patient medical records with reasonable rates of surveillance, consistency of the statistical methods used, and masked judging of the age at cataract surgery. Furthermore, patients and controls were recruited from the same population, which increases the consistency of the results. Glaucomatous patients were in close follow-up and their frequent slit-lamp examination enabled early detection of the cataract progression. However, there are also limitations to be mentioned. This study as a retrospective analysis cannot demonstrate causation. The analysis was conducted as a single-center study with potential subjective bias in surgical decisions. Moreover, since the patients were already in senile age group, the fact that they already had lens changes cannot be denied.

Ideally, young patients receiving IOP-lowering treatment should be recruited. Thus, cataract formation can be estimated irrespective of normal lens aging.

The effects of drug instillation frequency and preservatives are not examined in this study. The cataract morphological characteristics were not further correlated with the timing of cataract extraction.

Moreover, this study did not specifically look at other concomitant conditions which may predispose to glaucoma development and also affect the lens by histochemical changes or hemodynamic alterations at the anterior segment, such as pseudoexfoliation syndrome.⁴⁰ The pathomechanism underlying any potential association between antiglaucomatous therapy and cataract formation remains unclear. However, some possible explanations might be speculated; a reduction in aqueous humor production can result in reduced oxygen supplies for lens metabolic needs. Since cataract etiology is not fully understood, shifts in aqueous humor hydrodynamics and its association with cataract development may lead to more insights into the underlying mechanisms of cataract disease.

CONCLUSION

In summary, findings from our analysis add indirect evidence to the hypothesis that chronic topical β -blocker use may increase the risk of cataract formation. In future research, prospective, randomized trials are needed to examine the effect of IOP-lowering medication and cataract formation and progression. Since the pharmacological toxicity of antiglaucomatous medications may be cumulative, it is important to examine the time interval during which the patients are exposed and its potential correlation with cataract development.

CLINICAL SIGNIFICANCE

Our study findings suggest that the risk of developing a cataract should be taken under consideration when accessing a patient on topical antiglaucoma drug. Patients should be carefully evaluated regarding their age and overall health when first administered with an antiglaucomatous agent.

REFERENCES

1. Asbell PA, Dualan I, Mindel J, Brocks D, Ahmad M, Epstein S. Age-related cataract. *Lancet*. 2005 Feb 12-18;365(9459):599-609.
2. Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, Nickerson RJ, Pool J, Colton TL, Ganley JP, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. *Surv Ophthalmol* 1980 May-Jun;24(Suppl):335-610.

3. Hyman L, Wu SY, Connell AM, Schachat A, Nemesure B, Hennis A, Leske MC. Prevalence and causes of visual impairment in The Barbados Eye Study. *Ophthalmology* 2001 Oct;108(10):1751-1756.
4. Varma R, Ying-Lai M, Klein R, Azen SP. Prevalence and risk indicators of visual impairment and blindness in Latinos: the Los Angeles Latino Eye Study. *Ophthalmology* 2004 Jun;111(6):1132-1140.
5. Zhao J, Ellwein LB, Cui H, Ge J, Guan H, Lv J, Ma X, Yin J, Yin ZQ, Yuan Y, et al. Prevalence of vision impairment in older adults in rural China: the China Nine-Province Survey. *Ophthalmology* 2010 Mar;117(3):409-416, 416.e401.
6. Murthy GV, Gupta S, Ellwein LB, Munoz SR, Bachani D, Dada VK. A population-based eye survey of older adults in a rural district of Rajasthan: I. Central vision impairment, blindness, and cataract surgery. *Ophthalmology* 2001 Apr;108(4):679-685.
7. Zheng Y, Lavanya R, Wu R, Wong WL, Wang JJ, Mitchell P, Cheung N, Cajucom-Uy H, Lamoureux E, Aung T, et al. Prevalence and causes of visual impairment and blindness in an urban Indian population: the Singapore Indian eye study. *Ophthalmology* 2011 Sep;118(9):1798-1804.
8. European Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed. 2014. Available from: <http://www.eugs.org/>.
9. Aptel F, Chiquet C, Romanet J-P. Intraocular pressure-lowering combination therapies with prostaglandin analogues. *Drugs* 2012 Jul 9;72(10):1355-1371.
10. Irkec M, Bozkurt B, Mocan MC. Are preservatives necessary to improve efficacy of some glaucoma drops? *Br J Ophthalmol* 2013 Dec;97(12):1493-1494.
11. Schmidl D, Schmetterer L, Garhöfer G, Popa-Cherecheanu A. Pharmacotherapy of glaucoma. *J Ocul Pharmacol Ther* 2015 Mar;31(2):63-77.
12. Brubaker RF, Schoff EO, Nau CB, Carpenter SP, Chen K, Vandenberg AM. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. *Am J Ophthalmol* 2001 Jan;131(1):19-24.
13. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. *Surv Ophthalmol* 2002 Aug;47 (Suppl 1):S53-S64.
14. Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. *Ophthalmology* 2004 Sep;111(9):1658-1662.
15. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. *Ophthalmology* 2008 May;115(5):790-795.e4.
16. Potter DE, Crosson CE, Heath AR, Ogidigben MJ. Review: alpha 2 and DA2 agonists as antiglaucoma agents: comparative pharmacology and clinical potential. *J Ocul Pharmacol* 1990 Fall;6(3):251-257.
17. Greenfield DS, Liebmann JM, Ritch R. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. *J Glaucoma* 1997 Aug;6(4):250-258.
18. Feng H, Adelman RA. Cataract formation following vitreo-retinal procedures. *Clin Ophthalmol* 2014 Sep 23;8:1957-1965.
19. Foster CS, Barrett F. Cataract development and cataract surgery in patients with juvenile rheumatoid arthritis-associated iridocyclitis. *Ophthalmology* 1993 Jun;100(6):809-817.
20. Delcourt C, Cristol JP, Tessier F, Leger CL, Michel F, Papoz L. Risk factors for cortical, nuclear, and posterior subcapsular cataracts: the POLA study. *Pathologies Oculaires Liees à l'Age*. *Am J Epidemiol* 2000 Mar 1;151(5):497-504.
21. Leske MC, Chylack LT Jr, Wu SY. The lens opacities case-control study. Risk factors for cataract. *Arch Ophthalmol* 1991 Feb;109(2):244-251.
22. Mukesh BN, Le A, Dimitrov PN, Ahmed S, Taylor HR, McCarty CA. Development of cataract and associated risk factors: the Visual Impairment Project. *Arch Ophthalmol* 2006 Jan;124(1):79-85.
23. Hennis A, Wu SY, Nemesure B, Leske MC. Risk factors for incident cortical and posterior subcapsular lens opacities in the Barbados Eye Studies. *Arch Ophthalmol* 2004 Apr;122(4):525-530.
24. Klein BE, Klein R, Lee KE. Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: the Beaver Dam Eye Study. *Am J Ophthalmol* 1998 Dec;126(6):782-790.
25. Tan JS, Wang JJ, Mitchell P. Influence of diabetes and cardiovascular disease on the long-term incidence of cataract: the Blue Mountains Eye Study. *Ophthalmic Epidemiol* 2008 Sep-Oct;15(5):317-327.
26. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. *N Engl J Med* 1997 Jul 3;337(1):8-14.
27. Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. *Ophthalmology* 2009 Apr;116(4):652-657.
28. Urban RC, Cotlier R. Corticosteroid-induced cataracts. *Surv Ophthalmol* 1986 Sep-Oct;31(2):102-110.
29. Tuft SJ, Bunce C. Axial length and age at cataract surgery. *J Cataract Refract Surg* 2004 May;30(5):1045-1048.
30. Stewart WC, Stewart JA, Jackson AL. Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy. *Acta Ophthalmol Scand* 2002 Jun;80(3):277-281.
31. Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. *Ophthalmology* 2000 Jun;107(6):1171-1177.
32. Maclure GM. Chronic open angle glaucoma treated with Timolol. A four year study. *Trans Ophthalmol Soc UK* 1983; 103(Pt 1):78-83.
33. Mitchell P, Wang JJ, Cumming RG, House P, England JD. Long-term topical timolol and blood lipids: the Blue Mountains Eye Study. *J Glaucoma* 2000 Apr;9(2):174-178.
34. Weissman SS, Asbell PA. Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivity. *Br J Ophthalmol* 1990 Jul;74(7):409-412.
35. Mehta M, Siddique SS, Gonzalez-Gonzalez LA, Foster CS. Immunohistochemical differences between normal and chronically inflamed conjunctiva: diagnostic features. *Am J Dermatopathol* 2011 Dec;33(8):786-789.
36. Henriksson JT, De Paiva CS, Farley W, Pflugfelder SC, Burns AR, Bergmanson JP. Morphologic alterations of the palpebral conjunctival epithelium in a dry eye model. *Cornea* 2013 Apr;32(4):483-490.
37. Ayyala RS, Cruz DA, Margo CE, Harman LE, Pautler SE, Misch DM, Mines JA, Richards DW. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. *Am J Ophthalmol* 1998 Oct;126(4):602-604.

38. Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. *Ophthalm Plast Reconstr Surg* 2008 Jul-Aug;24(4):302-307.
39. Mukhopadhyay P, Bhattacharjee P, Andom T, Geoghegan TE, Andley UP, Paterson CA. Expression of prostaglandin receptors EP4 and FP in human lens epithelial cells. *Invest Ophthalmol Vis Sci* 1999 Jan;40(1):105-112.
40. Detorakis ET, Acharopoulos AK, Drakonaki EE, Kozobolis VP. Hemodynamic evaluation of the posterior ciliary circulation in exfoliation syndrome and exfoliation glaucoma. *Graefes Arch Clin Exp Ophthalmol* 2007 Apr;245(4):516-521.